Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Gastrointest Oncol. Feb 15, 2021; 13(2): 119-130
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119

Table 1 Patient characteristics

Characteristic		Standard therapy, n = 72, (%)	TNT, n = 89, (%)	P value
Age in year	< 65	29 (40)	66 (74)	< 0.001
	≥ 65	43 (60)	23 (26)	< 0.001
	Range	40-84	33-79
	mean [SD]	65.4 [10.5]	57.5 [10.1]	< 0.001
Sex	M	45 (63)	54 (61)	0.813
	F	27 (38)	35 (39)	0.813
PS WHO	0	48 (67)	67 (75)	0.229
	1	24 (33)	22 (25)	0.229
High-risk factors for failure	cT4	15 (21)	33 (37)	0.025
	cN2	49 (68)	62 (70)	0.827
	MRF+	39 (54)	66 (74)	0.008
	EMVI+	27 (38)	65 (73)	< 0.001
	Lateral node	15 (21)	8 (9)	0.033
cTN	T2N2	1 (1)	1 (1)	0.138¹
	T3N0	1 (1)	0 (0)
	T3N1	21 (29)	20 (22)
	T3N2	34 (47)	35 (39)
	T4N1	1 (1)	7 (8)
	T4N2	14 (19)	26 (29)
Distance from anal verge in cm	≤ 5	27 (38)	29 (33)	0.370
	5.1-10	37 (51)	43 (48)
	≥ 10.1	8 (11)	17 (19)

¹Likelihood-ratio test.

EMVI: Extramural vascular invasion; MRF: Mesorectal fascia; PS: Performance status; TNT: Total neoadjuvant treatment; WHO: World Health Organization.

Citation: Tuta M, Boc N, Brecelj E, Peternel M, Velenik V. Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 2021; 13(2): 119-130
URL: https://www.wjgnet.com/1948-5204/full/v13/i2/119.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i2.119

Tuta M, Boc N, Brecelj E, Peternel M, Velenik V. Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 2021; 13(2): 119-130 [PMID: 33643528 DOI: 10.4251/wjgo.v13.i2.119]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.